Andrew M Skinner

935 total citations · 1 hit paper
26 papers, 587 citations indexed

About

Andrew M Skinner is a scholar working on Infectious Diseases, Epidemiology and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Andrew M Skinner has authored 26 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 20 papers in Epidemiology and 9 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Andrew M Skinner's work include Clostridium difficile and Clostridium perfringens research (25 papers), Microscopic Colitis (20 papers) and Nosocomial Infections in ICU (9 papers). Andrew M Skinner is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (25 papers), Microscopic Colitis (20 papers) and Nosocomial Infections in ICU (9 papers). Andrew M Skinner collaborates with scholars based in United States, Switzerland and Canada. Andrew M Skinner's co-authors include Stuart Johnson, Mark H. Wilcox, Kevin W. Garey, Ciarán P. Kelly, Valéry Lavergne, Anne J Gonzales-Luna, Dale N. Gerding, Lance R. Peterson, Susan P. Sambol and B. J. Owen and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Andrew M Skinner

21 papers receiving 581 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

2021 383 citations Stuart Johnson, Valéry Lavergne et al. Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by Andrew M Skinner

Since Specialization

Citations

This map shows the geographic impact of Andrew M Skinner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew M Skinner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew M Skinner more than expected).

Fields of papers citing papers by Andrew M Skinner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew M Skinner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew M Skinner. The network helps show where Andrew M Skinner may publish in the future.

Co-authorship network of co-authors of Andrew M Skinner

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew M Skinner. A scholar is included among the top collaborators of Andrew M Skinner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew M Skinner. Andrew M Skinner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Three stages of laboratory stewardship in improving appropriate Clostridioides difficile testing in a community-based setting 2025 ·Antimicrobial Stewardship & Healthcare Epidemiology ·Michael Wang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Joe Brown, (unknown), (unknown), Andrew M Skinner	0
2	Enteritis necroticans and Clostridium perfringens type C; Epidemiological and pathological findings over the past 20 years 2025 ·PLoS neglected tropical diseases ·Stuart Johnson, Andrew M Skinner, (unknown), Trevor Duke, Horst Posthaus	0
3	Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital 2025 ·Clinical Infectious Diseases ·Sarah N. Redmond, Jennifer L. Cadnum, Annette Jencson, (unknown), Brigid Wilson, Andrew M Skinner, Amy S. Gargis, (unknown), (unknown), Piyali Chatterjee, Chetan Jinadatha, Curtis J. Donskey	4
4	Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures 2024 ·Antimicrobial Agents and Chemotherapy ·(unknown), Andrew M Skinner, Adam Cheknis, (unknown), Vanessa Stevens, Lorinda M. Wright, Dale N. Gerding, Stuart Johnson	2
5	Risk of rehospitalization due to Clostridioides difficile infection among hospitalized patients with Clostridioides difficile: a cohort study 2024 ·Infection Control and Hospital Epidemiology ·(unknown), Stuart Johnson, Larry H. Danziger, Andrew M Skinner	0
6	Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study 2024 ·Open Forum Infectious Diseases ·Kelly R. Reveles, Anne J Gonzales-Luna, Yoav Golan, Carolyn D. Alonso, (unknown), Xing Tan, Monique R. Bidell, (unknown), Carl V. Crawford, Andrew M Skinner	1
7	Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin 2023 ·Microbiology Spectrum ·Susan P. Sambol, Andrew M Skinner, (unknown), B. J. Owen, Dale N. Gerding, Stuart Johnson	9
8	Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials 2023 ·Journal of Antimicrobial Chemotherapy ·Andrew M Skinner, (unknown), Adam Cheknis, Stuart Johnson	4
9	Characteristics and outcomes of Clostridioides difficile infection after a change in the diagnostic testing algorithm 2023 ·Infection Control and Hospital Epidemiology ·(unknown), Lorinda M. Wright, Adam Cheknis, Stuart Johnson, (unknown), Andrew M Skinner	1
10	Effect of the COVID-19 Pandemic on Rates and Epidemiology of Clostridioides difficile Infection in One VA Hospital 2023 ·Antibiotics ·Lorinda M. Wright, Andrew M Skinner, Adam Cheknis, (unknown), Ling Ge, (unknown), David J. Leehey, Dale N. Gerding, Stuart Johnson	4
11	Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI 2023 ·Anaerobe ·Andrew M Skinner, Xing Tan, (unknown), (unknown), (unknown), Michael Wang, Stuart Johnson	0
12	Which trial do we need? A sequential multiple assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence 2023 ·Clinical Microbiology and Infection ·Joffrey van Prehn, Cornelis H. van Werkhoven, Andrew M Skinner, Benoît Guéry, Erik R. Dubberke, Ed J. Kuijper	1
13	Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection 2023 ·Journal of Clinical Gastroenterology ·Paul Feuerstadt, Carl V. Crawford, Xing Tan, (unknown), (unknown), (unknown), (unknown), Monique R. Bidell, Glenn Tillotson, Stuart Johnson, Andrew M Skinner	6
14	403. Strain Epidemiology of Clostridioides difficile across Three Geographically Distinct Medical Centers in Chicago 2022 ·Open Forum Infectious Diseases ·Do Young ‍Kim, Adam Cheknis, (unknown), Michael Y. Lin, Mary K. Hayden, Nicholas M. Moore, (unknown), Vera Tešić, Kathleen G. Beavis, Dale N. Gerding, Stuart Johnson, Andrew M Skinner	2
15	406. Vancomycin Activity against Clostridioides difficile Over Three Decades in Chicago 2022 ·Open Forum Infectious Diseases ·Andrew M Skinner, (unknown), Do Young Kim, (unknown), Stuart Johnson	1
16	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults 2021 ·Clinical Infectious Diseases ·Stuart Johnson, Valéry Lavergne, Andrew M Skinner, Anne J Gonzales-Luna, Kevin W. Garey, Ciarán P. Kelly, Mark H. Wilcox	123
17	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults breakdown → 2021 ·Clinical Infectious Diseases ·Stuart Johnson, Valéry Lavergne, Andrew M Skinner, Anne J Gonzales-Luna, Kevin W. Garey, Ciarán P. Kelly, Mark H. Wilcox	383
18	A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences 2021 ·Clinical Infectious Diseases ·Andrew M Skinner, Xing Tan, (unknown), Larry H. Danziger, Dale N. Gerding, Stuart Johnson	9
19	Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase in Clostridioides difficile detection and a trend toward increased strain diversity 2020 ·Infection Control and Hospital Epidemiology ·Andrew M Skinner, Brian Yu, Adam Cheknis, (unknown), Dale N. Gerding, Stuart Johnson	2
20	The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile 2020 ·Journal of Clinical Medicine ·Andrew M Skinner, (unknown), Michelle M. Merrigan, Kevin J. O’Leary, Susan P. Sambol, Farida Siddiqui, Lance R. Peterson, Dale N. Gerding, Stuart Johnson	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact